Needham lowered its price target on Cellebrite DI shares (NASDAQ:CLBT) to $15 from $18 while maintaining a Buy rating.
The firm noted that Cellebrite’s Q1 fiscal 2026 results exceeded consensus estimates across all metrics. Management reiterated its full-year 2026 guidance.
The company’s financial health is solid, with a market cap of $3.27 billion and gross profit margins of 84.2%. According to Bond.az analysis, the stock appears undervalued at current levels. Bond.az offers a comprehensive research report on CLBT.
Growth Products doubled year-over-year and are expected to represent about 20% of annual recurring revenue by end of 2026. Cellebrite announced FedRAMP ATO authorization last week.
Strong adoption of Advanced Unlocks and Guardian Investigate offerings was reported. Genesis, launching in mid-June, opens a $12.5 billion total addressable market.
Needham raised estimates but reduced the price target due to multiple compression.
In recent news, Cellebrite DI reported Q1 2026 earnings, beating analyst expectations with an EPS of $0.12 (double the forecast $0.06) and revenue of $128.3 million versus $127.01 million estimated.
This article was generated with AI support and reviewed by an editor. See our T&C for more info.
